伦博雷沙坦诱发的间质性肺病：病例报告。

IF 0.8 Q4 RESPIRATORY SYSTEM Respirology Case Reports Pub Date : 2024-04-25 eCollection Date: 2024-05-01 DOI:10.1002/rcr2.1334

Satoshi Nakahara, Yumiko Ishii, Reika Egashira, Kazuya Tsubouchi, Mikihiro Kohno, Tomoyoshi Takenaka, Kentaro Tanaka, Isamu Okamoto

{"title":"伦博雷沙坦诱发的间质性肺病：病例报告。","authors":"Satoshi Nakahara, Yumiko Ishii, Reika Egashira, Kazuya Tsubouchi, Mikihiro Kohno, Tomoyoshi Takenaka, Kentaro Tanaka, Isamu Okamoto","doi":"10.1002/rcr2.1334","DOIUrl":null,"url":null,"abstract":"We report the first case of drug-induced interstitial lung disease attributed to lemborexant. A 66-year-old man reported to our hospital with the acute onset of cough and breathlessness with ground-glass opacity on radiological examination. Symptoms were identified after taking lemborexant for 2 consecutive days. The patient had undergone lemborexant treatment 2 years prior and had exhibited no symptoms at that time. The drug-induced lymphocyte stimulation test for lemborexant was positive. He showed rapid improvement upon treatment with steroid. With the rise in prescriptions of lemborexant for insomnia, lemborexant should be considered as a possible cause of drug-induced interstitial lung disease.","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11045439/pdf/","citationCount":"0","resultStr":"{\"title\":\"Lemborexant-induced interstitial lung disease: A case report.\",\"authors\":\"Satoshi Nakahara, Yumiko Ishii, Reika Egashira, Kazuya Tsubouchi, Mikihiro Kohno, Tomoyoshi Takenaka, Kentaro Tanaka, Isamu Okamoto\",\"doi\":\"10.1002/rcr2.1334\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We report the first case of drug-induced interstitial lung disease attributed to lemborexant. A 66-year-old man reported to our hospital with the acute onset of cough and breathlessness with ground-glass opacity on radiological examination. Symptoms were identified after taking lemborexant for 2 consecutive days. The patient had undergone lemborexant treatment 2 years prior and had exhibited no symptoms at that time. The drug-induced lymphocyte stimulation test for lemborexant was positive. He showed rapid improvement upon treatment with steroid. With the rise in prescriptions of lemborexant for insomnia, lemborexant should be considered as a possible cause of drug-induced interstitial lung disease.\",\"PeriodicalId\":45846,\"journal\":{\"name\":\"Respirology Case Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-04-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11045439/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respirology Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/rcr2.1334\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/rcr2.1334","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

摘要

我们报告了首例由药物利眠宁诱发的间质性肺病。一名 66 岁的男子因咳嗽和呼吸困难急性发作并伴有放射性检查显示的磨玻璃状不透明而到我院就诊。症状是在连续两天服用利眠宁后出现的。患者两年前曾接受过利博昔康治疗，当时没有任何症状。药物诱导的淋巴细胞刺激试验对利博昔坦呈阳性反应。他在接受类固醇治疗后病情迅速好转。随着治疗失眠的利眠宁处方量的增加，应将利眠宁视为药物诱发间质性肺病的可能原因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Lemborexant-induced interstitial lung disease: A case report.

We report the first case of drug-induced interstitial lung disease attributed to lemborexant. A 66-year-old man reported to our hospital with the acute onset of cough and breathlessness with ground-glass opacity on radiological examination. Symptoms were identified after taking lemborexant for 2 consecutive days. The patient had undergone lemborexant treatment 2 years prior and had exhibited no symptoms at that time. The drug-induced lymphocyte stimulation test for lemborexant was positive. He showed rapid improvement upon treatment with steroid. With the rise in prescriptions of lemborexant for insomnia, lemborexant should be considered as a possible cause of drug-induced interstitial lung disease.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Respirology Case Reports RESPIRATORY SYSTEM-

CiteScore

1.40

自引率

0.00%

发文量

178

审稿时长

8 weeks

期刊介绍： Respirology Case Reports is an open-access online journal dedicated to the publication of original clinical case reports, case series, clinical images and clinical videos in all fields of respiratory medicine. The Journal encourages the international exchange between clinicians and researchers of experiences in diagnosing and treating uncommon diseases or diseases with unusual presentations. All manuscripts are peer-reviewed through a streamlined process that aims at providing a rapid turnaround time from submission to publication.